long-acting erythropoietin (HM10760A) / Hanmi 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   2 News 
  • ||||||||||  long-acting erythropoietin (HM10760A) / Hanmi
    Preclinical, Journal:  Single-and repeat-dose toxicity of HM10760A, a long-acting erythropoietin, in rats and monkeys. (Pubmed Central) -  Jan 7, 2021   
    Almost all observations recorded at the low- and mid-dose levels are typical pharmacological effects of EPO and not uniquely attributed HM10760A toxicity. To account for the differences between human being and animal physiologies, the safety of HM10760A needs to be further confirmed in future clinical studies.
  • ||||||||||  long-acting erythropoietin (HM10760A) / Hanmi
    Trial completion:  A Study of HM10760A (Long-acting Erythropoietin (EPO)) in Healthy Korean Subjects (clinicaltrials.gov) -  Sep 27, 2011   
    P1,  N=48, Completed, 
    To account for the differences between human being and animal physiologies, the safety of HM10760A needs to be further confirmed in future clinical studies. Recruiting --> Completed